OPN1MW and Anxiety: The 12-week open-label multi-site trial, which administered transdermal CBD gel (50 mg/day (n = 1); 100 mg/day (n = 3); 250 mg/day (n = 16)) to 20 children (aged 6–17 years), reported a significant reduction in anxiety and behaviour symptoms.